MNV
Market News Video
MNV MNV 10 Stocks Crossing Above Their 200 Day Moving Average
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

ChemoCentryx Becomes Oversold (CCXI)
Friday, September 4, 11:58 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

ChemoCentryx Becomes Oversold (CCXI)
Friday, September 4, 11:58 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

CCXI Makes Notable Cross Below Critical Moving Average
Friday, September 4, 1:50 PM ET, by Market News Video Staff

In trading on Friday, shares of ChemoCentryx, Inc. (CCXI) crossed below their 200 day moving ...

Investors Land CCXI 16.3% Cheaper Than Its Secondary Stock Offering
Thursday, September 10, 1:11 PM ET, by Market News Video Staff

Looking back to 92 days ago, ChemoCentryx, Inc. (CCXI) priced a 5,200,000 share secondary stock ...

Sum Up The Parts: ESGV Could Be Worth $67
Wednesday, September 30, 8:00 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Pick Up This Bargain Even Cheaper Than EVP, Chief Operating Officer Butt Did

By Market News Video Staff, Wednesday, May 12, 10:03 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on May 7, ChemoCentryx, Inc.'s EVP, Chief Operating Officer, Tausif Butt, invested $120,240.68 into 10,870 shares of CCXI, for a cost per share of $11.06. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

In trading on Wednesday, bargain hunters could buy shares of ChemoCentryx, Inc. (NASDAQ:CCXI) and achieve a cost basis 4.5% cheaper than Butt, with shares changing hands as low as $10.56 per share. ChemoCentryx, Inc. shares are currently trading up about 0.5% on the day. The chart below shows the one year performance of CCXI shares, versus its 200 day moving average:

ChemoCentryx, Inc. Chart

Looking at the chart above, CCXI's low point in its 52 week range is $9.55 per share, with $70.29 as the 52 week high point — that compares with a last trade of $10.78. By comparison, below is a table showing the prices at which CCXI insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
05/07/2021 Tausif Butt EVP, Chief Operating Officer 10,870 $11.06 $120,240.68

Free Report: Top 7%+ Dividends (paid monthly)


This Article's Word Cloud:   Back   Bargain   Bargains   Butt   CCXI   Cheaper   ChemoCentryx   Chief   Dividends   Free   Insider   Insiders   Looking   Officer   Operating   Price   Purchased   Report   Share   Shares   Start   Street   Tausif   Than   There   Title   Value   Wall   Wednesday   about   above   achieve   below   buying   chart   cost   hunters   insider   last   only   point   reason   share   shares   stock   that   their   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Pick Up This Bargain Even Cheaper Than EVP, Chief Operating Officer Butt Did | Market News Video | Copyright © 2008 - 2021, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.